Linagliptin

Therapeutic Group

Blood Glucose Lowering Drugs, Excluding Insulin

Indication Dosage

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, used in the management of type 2 diabetes mellitus. As a selective and potent DPP-4 inhibitor, it enhances glycemic control by increasing endogenous incretin hormones, such as GLP-1 and GIP, which stimulate insulin release and reduce glucagon secretion. Linagliptin is characterized by its once-daily dosing regimen, a low potential for drug-drug interactions, and a favorable side effect profile. It is a valuable therapeutic option for individuals with type 2 diabetes who require adjunctive treatment to improve blood glucose control while minimizing the risk of hypoglycemia and other adverse effects.

Dosage:

  • Adult: 5mg Once Daily.

Content

  • Tab 5mg: Linagliptin 50mg

Pregnancy

Contraindicated in Pregnancy

Stability

  • Dipeptidyl Peptidase-4 Inhibitor

Contra Indications

  • Linagliptin is contraindicated in patients with a history of a hypersensitivity reaction to linagliptin or its components.

Precautions

  • Linagliptin is contraindicated in patients with a history of a hypersensitivity reaction to linagliptin or its components.

Lactation

  • Contraindicated or Not Recommended

Side Effects

  • Cough
  • Nasopharyngitis
  • Pancreatitis Discontinue if Symptoms of Acute Pancreatitis

Available Brands